Marketing-authorisation holder · United States
Merck Sharp & Dohme LLC
45 medicines in 1 country, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
45 medicines in 1 country, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 45
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Antivenin (Latrodectus mactans)Nlt6000u · For Injection | Antivenin | United States | Marketed | 1936 |
| Antivenin (Latrodectus mactans)Nlt6000u · For Injection | Antivenin | United States | Marketed | 1936 |
| CAPVAXIVE84ug/.5ml · Injection | Pneumococcal conjugate vaccine | United States | Marketed | 2024 |
| Ervebo1ML · Injection | Ebola zaire vaccine, live | United States | Marketed | 2019 |
| Gardasil120mcg l1 protein from hpv 6, 11, 16 and 18 ug/.5ml · Injection | Human papillomavirus quadrivalent (types, Vaccine, recombinant | United States | Not marketed | 2006 |
| Gardasil 90.5ml · Injection | Human papillomavirus vaccine, recombinant | United States | Marketed | 2014 |
| Gardasil 90.5ml · Injection | Human papillomavirus vaccine, recombinant | United States | Marketed | 2014 |
| M-M-R Ii0.5ml · For Injection | Measles, mumps, Rubella virus vaccine live | United States | Marketed | 1971 |
| M-M-R Ii0.5ml · For Injection | Measles, mumps, Rubella virus vaccine live | United States | Marketed | 2023 |
| N/A1ML · Injection | Normal horse serum | United States | Marketed | 1959 |
| Pedvaxhib7.5ug/.5ml · Injection | Haemophilus b conjugate vaccine | United States | Marketed | 1989 |
| Pneumovax 2325ug/.5ml · Injection | Pneumococcal vaccine polyvalent | United States | Marketed | 1977 |
| Pneumovax 2325ug/.5ml · Injection | Pneumococcal vaccine polyvalent | United States | Marketed | 1977 |
| Proquad0.5ml · For Injection | Measles, mumps, rubella, Varicella virus vaccine live | United States | Marketed | 2023 |
| Proquad0.5ml · For Injection | Measles, mumps, rubella, Varicella virus vaccine live | United States | Marketed | 2005 |
| Recombivax, Recombivax Hb10ug/ml · Injection | Hepatitis b vaccine | United States | Marketed | 1996 |
| Recombivax, Recombivax Hb5ug/0.5ml · Injection | Hepatitis b vaccine | United States | Marketed | 1996 |
| Recombivax, Recombivax Hb10ug/ml · Injection | Hepatitis b vaccine | United States | Marketed | 1986 |
| Recombivax, Recombivax Hb40ug/ml · Injection | Hepatitis b vaccine | United States | Marketed | 1986 |
| Recombivax, Recombivax Hb5ug/0.5ml · Injection | Hepatitis b vaccine | United States | Marketed | 1986 |
| Rotateq2.2x10e6 iu · Suspension | Rotavirus vaccine, live, oral, pentavalent | United States | Marketed | 2006 |
| Rotateq2.2x10e6 iu · Suspension | Rotavirus vaccine, live, oral, pentavalent | United States | Marketed | 2006 |
| Vaqta25u/.5ml · Injection | Hepatitis a vaccine, inactivated | United States | Marketed | 1996 |
| Vaqta50u/ml · Injection | Hepatitis a vaccine, inactivated | United States | Marketed | 1996 |
| Vaqta25u/.5ml · Injection | Hepatitis a vaccine, inactivated | United States | Marketed | 1996 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 45 | 30 | 15 | CompaniesAll medicines |
Also in the registers of Brazil, Saudi Arabia, Singapore
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.